RU2019131252A3 - - Google Patents

Download PDF

Info

Publication number
RU2019131252A3
RU2019131252A3 RU2019131252A RU2019131252A RU2019131252A3 RU 2019131252 A3 RU2019131252 A3 RU 2019131252A3 RU 2019131252 A RU2019131252 A RU 2019131252A RU 2019131252 A RU2019131252 A RU 2019131252A RU 2019131252 A3 RU2019131252 A3 RU 2019131252A3
Authority
RU
Russia
Application number
RU2019131252A
Other languages
Russian (ru)
Other versions
RU2019131252A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019131252A publication Critical patent/RU2019131252A/ru
Publication of RU2019131252A3 publication Critical patent/RU2019131252A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
RU2019131252A 2017-03-28 2018-03-28 Пептидные вакцины на основе pd1 человека и их применение RU2019131252A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477895P 2017-03-28 2017-03-28
US62/477,895 2017-03-28
PCT/US2018/024831 WO2018183488A1 (en) 2017-03-28 2018-03-28 Human pd1 peptide vaccines and uses thereof

Publications (2)

Publication Number Publication Date
RU2019131252A RU2019131252A (ru) 2021-04-28
RU2019131252A3 true RU2019131252A3 (cg-RX-API-DMAC7.html) 2021-06-01

Family

ID=63678120

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019131252A RU2019131252A (ru) 2017-03-28 2018-03-28 Пептидные вакцины на основе pd1 человека и их применение

Country Status (11)

Country Link
US (1) US11684660B2 (cg-RX-API-DMAC7.html)
EP (1) EP3600398B1 (cg-RX-API-DMAC7.html)
JP (1) JP7346302B2 (cg-RX-API-DMAC7.html)
KR (1) KR102653567B1 (cg-RX-API-DMAC7.html)
CN (2) CN110636855B (cg-RX-API-DMAC7.html)
AU (2) AU2018243920B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019020386A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058393A1 (cg-RX-API-DMAC7.html)
ES (1) ES2963635T3 (cg-RX-API-DMAC7.html)
RU (1) RU2019131252A (cg-RX-API-DMAC7.html)
WO (1) WO2018183488A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512966A (ja) * 2018-02-07 2021-05-20 イミュジーン、リミテッドImugene Limited ワクチン組成物およびその使用
WO2020071869A1 (ko) * 2018-10-05 2020-04-09 알엔에이진 주식회사 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도
BR112022005044A2 (pt) 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
WO2023205796A2 (en) * 2022-04-21 2023-10-26 Ohio State Innovation Foundation Human ctla-4 peptide vaccines and uses thereof
WO2024211745A1 (en) * 2023-04-05 2024-10-10 Ohio State Innovation Foundation Human pd1, pd-l1, and ctla-4 combination peptide vaccines and uses thereof
CN119019569B (zh) * 2024-08-19 2025-10-24 中国人民解放军陆军军医大学 一种可定向增强胸腺新生t细胞杀伤乳腺癌的多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (cg-RX-API-DMAC7.html) 1968-10-17 1970-08-24
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
CN1215404A (zh) * 1996-04-03 1999-04-28 佩普里瑟奇公司 非树状骨架肽载体
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
CA2534060C (en) * 2003-07-30 2012-06-12 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
GB0400440D0 (en) * 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1912680B1 (en) 2005-06-15 2014-11-26 The Ohio State University Research Foundation Her-2 peptides
NZ582823A (en) * 2007-07-27 2012-04-27 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
WO2010011315A2 (en) * 2008-07-25 2010-01-28 Viral Genetics, Inc. Proteins for use in diagnosing and treating infection and disease
US20100234283A1 (en) * 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
RU2623161C2 (ru) * 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
EP2744830A4 (en) * 2012-06-21 2015-06-17 Compugen Ltd LSR ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER
CA2884704C (en) * 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
WO2014161509A1 (en) * 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
DK2992020T3 (da) * 2013-05-03 2020-02-10 Ohio State Innovation Foundation Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
TWI676636B (zh) * 2013-07-12 2019-11-11 Vlp醫療股份有限公司 包含pd-1抗原或pd-1配體抗原的類病毒粒子
TWI720946B (zh) 2014-08-08 2021-03-11 美商Vlp醫療股份有限公司 包含改質套膜蛋白質e3之類病毒粒子
EP3177640B1 (en) * 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
CA2971734C (en) * 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies

Also Published As

Publication number Publication date
US11684660B2 (en) 2023-06-27
KR102653567B1 (ko) 2024-04-02
EP3600398A1 (en) 2020-02-05
WO2018183488A1 (en) 2018-10-04
CN110636855A (zh) 2019-12-31
CN118909082A (zh) 2024-11-08
CN110636855B (zh) 2024-08-09
KR20190137826A (ko) 2019-12-11
ES2963635T3 (es) 2024-04-01
AU2025201760A1 (en) 2025-05-22
JP7346302B2 (ja) 2023-09-19
AU2018243920B2 (en) 2024-12-12
RU2019131252A (ru) 2021-04-28
EP3600398B1 (en) 2023-09-13
US20200197498A1 (en) 2020-06-25
BR112019020386A2 (pt) 2020-06-09
EP3600398A4 (en) 2020-12-30
CA3058393A1 (en) 2018-10-04
AU2018243920A1 (en) 2019-10-31
JP2020512375A (ja) 2020-04-23

Similar Documents

Publication Publication Date Title
BR122021000189A2 (cg-RX-API-DMAC7.html)
BR112019008823A2 (cg-RX-API-DMAC7.html)
BR112019025875B1 (pt) Sistema de cilindro com estrutura de ocupação de movimento relativo
BR112020011860B1 (pt) Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho
BR112020006283B1 (pt) Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico
BR112020009729B1 (pt) Inibidores de acss2 e métodos de uso dos mesmos
BR112020008714B1 (pt) Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus
BR112020006992B1 (pt) Dispositivo de recolhimento e método para o recolhimento de uma embarcação
BR112019023976B1 (pt) Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde
BR112020003112B1 (pt) Método de garantir a viabilidade de uma máquina para uma tarefa agendada
BR112020002577B1 (pt) Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo
BR112020001262B1 (pt) Processo para preparar uma composição de entrega de fármaco
BR112019016885B1 (pt) Remodelagem de imagem integrada e codificação de vídeo
BR112019027876B1 (pt) Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações
BR112019026818B1 (pt) Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador
BR112019026880B1 (pt) Método de comunicação, método para receber dados, e, dispositivo
BR102018011961B1 (pt) Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social
BR112019023944B1 (pt) Combinação farmacêutica para o tratamento de um câncer
BR112019021396B1 (pt) Processo para fabricação de pululano
BR102018003507B1 (pt) Sistema de isolamento de tensão de tambor de guincho
BR112019016182B1 (pt) Método para diagnosticar risco de revisão relacionado a implante
BR112019014127B1 (pt) Composição farmacêutica para tratamento de tumores
BR112019017156B1 (pt) Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador
BR102017026429B1 (pt) Método de extração subsequente de ácidos graxos e dna genômico a partir de dípteros
BR112020006250B1 (pt) Primeira estação base e método de controle de estado em uma primeira estação base